

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
WO2009132135 (B) US2009317361 EP2268642 KR2011004883 CN102015714 JP2011521903 EP2937350 KR2016138591	out 29, 2009	1'-Substituted carba-nucleoside analogs for antiviral treatment	Gilead Sciences, Inc.	Drug Substances	Hepatitis C (HCV)
WO2012012776 (B) US2012027752 CN103052631 EP2595980 KR2013091743 JP2013535453 US2015111839 US2015152116 CN105343098 KR2018012336 US10065958 US2019055251 IN201948034308 US10696679	jan 26, 2012	Methods and compounds for treating Paramyxoviridae virus infections	Gilead Sciences, Inc.	Methods of Use	Infection, paramyxovirus
WO2016069826 (B) US2016122374 US9724360 JP2017534614 CN113620992	mai 6, 2016	Methods for treating Filoviridae virus infections	Gilead Sciences, Inc.	Methods of Use	Ebola virus disease Marburg virus hemorrhagic fever
WO2016069827 (B)	mai 6, 2016	Methods for treating Filoviridae virus infections	Gilead Sciences, Inc.	Methods of Use	Ebola virus disease Marburg virus hemorrhagic fever
WO2017184668 (B)	out 26, 2017	Methods for treating Flaviviridae virus infections	Gilead Sciences, Inc.	Methods of Use	Infection, Zika virus
US2016361330 (B) US9949994	abr 24, 2018	Methods for treating Filoviridae virus infections	Gilead Sciences, Inc.	Methods of Use	Ebola virus disease Marburg virus hemorrhagic fever

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
WO2018204198 (B) US2018346504 KR2019141747 CN110636884 IN201917048029 EP3618929 JP2020518578 US10836787 US2021163523 IN202118042632	nov 8, 2018	Crystalline forms of (S)-2-ethylbutyl 2-(((S)-((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate	Gilead Sciences, Inc.	Drug Substances Polymorphs	Infection, viral
WO2019014247 (B) US2019083525 CN111093627 EP3651734 US10675296 US2020360420 US11266681	jan 17, 2019	Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections	Gilead Sciences, Inc.	Dosage Forms and Compositions	Infection, viral
US2018311263 (B) US10251898	abr 9, 2019	Methods for treating Filoviridae virus infections	Gilead Sciences, Inc.	Methods of Use	Viral hemorrhagic fever (filovirus infection)
CN109748943 (B)	mai 14, 2019	2'-C-Methyl substituted nucleoside compound and preparation and application thereof	Shanghai Institute of Materia Medica (SIMM)	Drug Substances Prodrugs	Cancer Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
US2019275063 (B) US10695357	set 12, 2019	Methods for treating Filoviridae virus infections	Gilead Sciences, Inc.	Methods of Use	Infection, viral
CN111116656 (B)	mai 8, 2020	Preparation method of remdesivir	Jiangsu Furui Kangtai Pharmaceutical Co., Ltd.	Prodrugs Synthesis	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111171078 (B)	mai 19, 2020	A synthesis method of remdesivir	Alpha Pharmaceuticals Co., Ltd. Jiangsu Province	Prodrugs Synthesis	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
CN111187269 (B)	mai 22, 2020	A synthesis method of remdesivir intermediate	Alpha Pharmaceuticals Co., Ltd. Jiangsu Province	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111205294 (B)	mai 29, 2020	A preparation method of remdesivir intermediate	Alpha Pharmaceuticals Co., Ltd. Jiangsu Province	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111205327 (B)	mai 29, 2020	A preparation method of remdesivir	Nanjing Finetech Chemical Co., Ltd.	Synthesis	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111233869 (B)	jun 5, 2020	New compound used for preparing remdesivir key intermediate and preparation method thereof	Hangzhou SIMBOS Pharm Co., Ltd.	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111233870 (B)	jun 5, 2020	Method for quickly preparing remdesivir medicine intermediate	University of Science and Technology of China (USTC)	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111233929 (B)	jun 5, 2020	Deuterium A nucleoside analogue and preparation method and use thereof	Chengdu Aqi Biopharma Technology Co., Ltd.	Drug Substances	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111233930 (B)	jun 5, 2020	A preparation method of remdesivir	Alpha Pharmaceuticals Co., Ltd. Jiangsu Province	Prodrugs Synthesis	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111233931 (B)	jun 5, 2020	A synthesis method of remdesivir	Suqian Shengji Pharmaceutical Technology Co., Ltd.	Synthesis	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
CN111269263 (B)	jun 12, 2020	A remdesivir side-chain intermediate and preparation method thereof	Knowshine (Shanghai) Pharmaceuticals Inc.	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111320650 (B)	jun 23, 2020	Derivatives of remdesivir and pharmaceutical use thereof	Nanjing Medical University (NMU)	Drug Substances Prodrugs	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111320662 (B)	jun 23, 2020	An N-benzyl substituted amidine derivatives and pharmaceutical use thereof	Nanjing Medical University (NMU)	Drug Conjugates Drug Substances	Infection, viral
US2020197422 (B)	jun 25, 2020	Methods for the preparation of ribosides	Gilead Sciences, Inc.	Prodrugs Synthesis Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
US2019255085 (B) US10695361	jun 30, 2020	Methods for treating Arenaviridae and Coronaviridae virus infections	Gilead Sciences, Inc.	Methods of Use	Coronavirus acute respiratory syndrome
CN111393243 (B)	jul 10, 2020	A medicine for phosphorus chiral synthesis method of nucleoside medicine and obtained by the method	Shenzhen Qianhai Boyang Research Institute Co., Ltd.	Prodrugs Synthesis	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111393314 (B)	jul 10, 2020	2-Alkyl-2-amino acid preparing method of creatine ester hydrochloride	Anhui Redwood Biomedical Technology Co., Ltd.	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111393392 (B)	jul 10, 2020	Synthesis of 2,3,5-tri-O-benzyl-D-ribo-1,4-lactone, a key intermediate of remdesivir	Henan Academy of Sciences High & New Technology Research Center, Henan Academy of Sciences Shanghai Micro-Mega Industrial Co., Ltd.	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
CN111393478 (B)	jul 10, 2020	A method for synthesizing new crown virus COVID-19 infection pneumonia medicine	Shenzhen Qianhai Boyang Research Institute Co., Ltd.	Prodrugs Synthesis	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111423443 (B)	jul 17, 2020	A 4-amino-7-iodine pyrrolo[2,1-f][1,2,4] the preparation method of triazine	Guangzhou Current Biotechnology Co., Ltd.	Prodrugs Synthesis Intermediates	Middle East respiratory syndrome coronavirus (MERS-CoV) infection Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111440176 (B)	jul 24, 2020	Synthesis method of metal complex promoted redisivir intermediate	Jiangsu University	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111470946 (B)	jul 31, 2020	A method to prepare a 2-ethyl-1-butanol intermediate for the synthesis of remdesivir	Suzhou Lixin Pharmaceutical Co., Ltd.	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111471070 (B)	jul 31, 2020	Synthesis method of remdesivir	Alpha Pharmaceuticals Co., Ltd. Jiangsu Province	Synthesis	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111494396 (B)	ago 7, 2020	Application of substituted amino metacetic acid ester compound in treating SARS-CoV-2 infection	Military Medical Institute Academy of Military Sciences PLA	Methods of Use	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111548328 (B)	ago 18, 2020	Method for preparing 2,3,5-tribenzyloxy-F-ribose acid-1, 4-lactone by oxidation in continuous flow micro-channel reactor	Alpha Pharmaceuticals Co., Ltd. Jiangsu Province	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111620876 (B)	set 4, 2020	Synthesis method of remdesivir key intermediate	Puji Biotechnology (Taizhou) Co., Ltd.	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
CN111620903 (B)	set 4, 2020	C-nucleoside analogues and preparation method of nitrile C-nucleoside compound for synthesizing remdesivir and application thereof	Anhui Biochem United Pharmaceutical Co., Ltd.	Prodrugs Synthesis Intermediates	Ebola virus disease Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111732618 (B)	out 2, 2020	A method to prepare a key intermediate for the synthesis of redemsivir	Zhenjiang Jujie New Material Technology Research and Development Center (Limited Partnership)	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
IN202011022634 (B)	out 9, 2020	Transmucosal dosage forms of remdesivir	Jubilant Generics Ltd.	Dosage Forms and Compositions	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111821310 (B)	out 27, 2020	Redisivir preparation and adaptation disease thereof	Venturepharm Laboratories Ltd.	Dosage Forms and Compositions	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111848427 (B)	out 30, 2020	Purifying method of L-alanine-2-ethyl butyl ester hydrochloride	Sichuan Tongsheng Biotechnology Co., Ltd.	Processes	Infection, viral
CN111848679 (B)	out 30, 2020	A method for synthesizing rudsivir by micro-channel reaction technology	Hangzhou Cheminspire Technologies Co., Ltd. Shandong Kechao Biopharmaceutical Co., Ltd.	Prodrugs Synthesis	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111875638 (B)	nov 3, 2020	A method to prepare a remdesivir derivative and its application	Jiangsu Institute of Nuclear Medicine	Diagnosis Synthesis	Diagnostics Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
US2020352967 (B) US11007208	nov 12, 2020	Methods for treating Arenaviridae and Coronaviridae virus infections	Gilead Sciences, Inc.	Methods of Use	Middle East respiratory syndrome coronavirus (MERS-CoV) infection Severe acute respiratory syndrome coronavirus (SARS-CoV) infection
CN111956630 (B)	nov 20, 2020	A liquid composition of powdered remdesivir, its preparation method and its application	Dalian University of Technology	Dosage Forms and Compositions	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111991374 (B)	nov 27, 2020	A redesivir inhalation aerosol and preparation method thereof	Dalian University of Technology	Dosage Forms and Compositions	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN111991375 (B)	nov 27, 2020	An inhalable liposomal formulation of atomized remdesivir and its preparation method	China Pharmaceutical University	Carrier-mediated drug delivery Dosage Forms and Compositions Nanotechnology	Severe acute respiratory syndrome coronavirus (SARS-CoV) infection
WO2020247633 (B) CN113993521 KR2022017937	dez 10, 2020	Thiarabine- and thiarabine prodrug-based treatments	Southern Research Institute	Antibodies Combination Products Prodrugs	Cancer, liver Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN112142810 (B)	dez 29, 2020	Nucleotide double amino phosphate compound, pharmaceutical composition and preparation method and application thereof	Foshan University	Drug Substances	Middle East respiratory syndrome coronavirus (MERS-CoV) infection Severe acute respiratory syndrome coronavirus (SARS-CoV) infection Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
CN112168956 (B)	jan 5, 2021	A preparation method of active peptide bactericidal antiviral spray	Hefei Tiantai Technology Co., Ltd.	Devices Dosage Forms and Compositions Natural Products Processes	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN112194661 (B)	jan 8, 2021	A preparation method of 4-amino-7-iodo-pyrrolo[2,1-f][1,2,4]triazine	Weihai Tongfeng Marine Biotechnology Co., Ltd.	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN112194680 (B)	jan 8, 2021	Nucleotide amino phosphate compound, pharmaceutical composition and preparation method and application thereof	Foshan University	Drug Substances	Middle East respiratory syndrome coronavirus (MERS-CoV) infection Severe acute respiratory syndrome coronavirus (SARS-CoV) infection Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN112194681 (B)	jan 8, 2021	Nucleotide long chain amino phosphate compound, pharmaceutical composition and preparation method and application thereof	Foshan University	Drug Substances	Middle East respiratory syndrome coronavirus (MERS-CoV) infection Severe acute respiratory syndrome coronavirus (SARS-CoV) infection Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN112250696 (B)	jan 22, 2021	A method for preparing radecevir key intermediate by using new micro-channel reactor	Nanjing Advanced Biomaterial and Process Equipment Research Institute Co., Ltd.	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
CN112274520 (B)	jan 29, 2021	Application of remdesivir in preparing medicine for treating idiopathic pulmonary fibrosis	Tianjin Jikun Pharmaceutical Technology Co., Ltd.	Methods of Use	Idiopathic pulmonary fibrosis
CN112279855 (B)	jan 29, 2021	A method for continuously preparing remdesivir intermediate by using micro-channel reactor	Nanjing Advanced Biomaterial and Process Equipment Research Institute Co., Ltd.	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN112300236 (B)	fev 2, 2021	Nucleotide mixed amino phosphate compound, pharmaceutical composition and application thereof	Foshan University	Drug Substances	Middle East respiratory syndrome coronavirus (MERS-CoV) infection Severe acute respiratory syndrome coronavirus (SARS-CoV) infection Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN112321589 (B)	fev 5, 2021	A synthesis method of anti-virus medicine remdesivir and intermediate thereof	Hangzhou Cheminspire Technologies Co., Ltd. Shandong Kechao Biopharmaceutical Co., Ltd.	Prodrugs Synthesis Synthesis Intermediates	Ebola virus disease Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN112358513 (B)	fev 12, 2021	A method for preparing redisivir intermediate by using continuous flow reactor	Shanghai Puyi Chem-Tech Co., Ltd.	Prodrugs Synthesis Intermediates	Ebola virus disease
CN112402371 (B)	fev 26, 2021	An injectable formulation of redemsivir and its preparation method	Nanjing Zenji Pharmaceutical Research Co., Ltd.	Dosage Forms and Compositions	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN112457318 (B)	mar 9, 2021	A method to synthesize a redemsivir intermediate	Nanjing Habo Medical Technology Co., Ltd.	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN112494500 (B)	mar 16, 2021	Application of remdesivir in preparing medicine for treating anti-tumour medicine heart toxicity	Beijing Jianmu Technology Co., Ltd.	Methods of Use	Cardiotoxicity

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
CN112500417 (B)	mar 16, 2021	A preparation method of 4-amino-pyrrolo[2,1-f][1,2,4]triazine	Shandong Chengchuang Blue Sea Pharmaceutical Technology Co., Ltd. Shandong Chenghui Shuangda Pharmaceutical Co., Ltd.	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN112500429 (B)	mar 16, 2021	A method to prepare an intermediate in the synthesis of remdesivir	Southeast University	Prodrugs Synthesis Intermediates	Middle East respiratory syndrome coronavirus (MERS-CoV) infection Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN112522203 (B)	mar 19, 2021	Cell vesicle for expressing chimeric antigen receptor and preparation method and application thereof	Fifth Affiliated Hospital Sun Yat-Sen University	Biological manufacturing process Cells	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN112618540 (B)	abr 9, 2021	Application of substituted indole compound in preparing anti- coronavirus preparation	Institute of Medicinal Biotechnology	Drug Substances	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN112618557 (B)	abr 9, 2021	Use of remdesivir in preparing medicines for treating diabetic complication	Beijing Jianmu Technology Co., Ltd.	Methods of Use	Atherosclerosis Coronary heart disease Diabetic nephropathy Hyperlipidemia
CN112625043 (B)	abr 9, 2021	Synthesis method of remdesivir intermediate triazine amine derivative	Lakestar PharmaTech Co., Ltd.	Prodrugs Synthesis Intermediates Carrier-mediated drug delivery	Coronavirus acute respiratory syndrome
CN112656759 (B)	abr 16, 2021	Redesivir eye drop and preparation method and use thereof	Henan Taifeng Biotechnology Co., Ltd.	Dosage Forms and Compositions	Infection, eye

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
CN112679542 (B)	abr 20, 2021	A method for preparing ratesivir by using a microchannel	Nanjing Advanced Biomaterial and Process Equipment Research Institute Co., Ltd.	Prodrugs Synthesis	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN112745324 (B)	mai 4, 2021	A method for synthesizing nucleoside analogues by continuous flow reactor	Acesys Pharmatech	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN112778310 (B)	mai 11, 2021	Use of nucleoside analogues or a combination preparation comprising nucleoside analogues for antiviral	Shanghai Institute of Materia Medica (SIMM) Wuhan Institute of Virology, Chinese Academy of Sciences	Drug Substances	Coronavirus acute respiratory syndrome Infection, Flavivirus Infection, respiratory syncytial virus (RSV) Influenza Viral hemorrhagic fever (filovrus infection)
US11013688 (B) WO2021239346	mai 25, 2021	Methods of treatment of viral diseases	Soft hale NV	Dosage Forms and Compositions	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN112844472 (B)	mai 28, 2021	Preparation method of chiral imidazole urea catalyst and application thereof	Shenzhen Feiyang Xingye Technology Co., Ltd.	Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN112876524 (B)	jun 1, 2021	Preparation method of redisivir intermediate	Shanghai Famo Biotechnology Co., Ltd.	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
US11020349 (B)	jun 1, 2021	Transmucosal dosage forms of remdesivir	Jubilant Generics Ltd.	Dosage Forms and Compositions	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
US2021161927 (B)	jun 3, 2021	Isomorphs of remdesivir and methods for synthesis of same	Anzalp Pharmsolutions Pvt. Ltd.	Prodrugs Synthesis	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN112979736 (B)	jun 18, 2021	A method to prepare remdesivir	Nanjing Ocean Pharmaceutical Technology Co., Ltd.	Prodrugs Synthesis	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
IN202011023385 (B)	jun 18, 2021	Pharmaceutical lipid compositions of remdesivir	Jubilant Generics Ltd.	Dosage Forms and Compositions	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
IN202114023358 (B)	jun 18, 2021	Transmucosal pharmaceutical compositions of antiviral drugs	Jubilant Generics Ltd.	Dosage Forms and Compositions	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN113004330 (B)	jun 22, 2021	Preparation method of high-purity redisivir	Qilu Pharmaceutical Co., Ltd.	Prodrugs Synthesis	Coronavirus acute respiratory syndrome
CN113121600 (B)	jul 16, 2021	Remdesivir dipolymer and preparation method and application thereof	Macau University of Science and Technology (MUST)	Drug Substances	Infection, viral
CN113143917 (B)	jul 23, 2021	New use of GC376 compound	Beijing Institute of Microbiology Chinese Center for Disease Control and Prevention (China CDC)	Combination Products	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN113143918 (B)	jul 23, 2021	Application of boloser in treating or improving new coronavirus pneumonia	Beijing Institute of Microbiology Chinese Center for Disease Control and Prevention (China CDC)	Combination Products	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN113149994 (B)	jul 23, 2021	Preparation method of redisivir intermediate and application thereof	Guangzhou Liushun Biotechnology Co., Ltd.	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
CN111265532 (B) US2021220377 EP3854403 WO2021147236 JP2021116295 US2021346411	jul 29, 2021	Substituted amino acid ester compound in the treatment of 2019-nCoV infection	Military Medical Institute Academy of Military Sciences PLA	Methods of Use	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
US2021228605 (B)	jul 29, 2021	Isomorphs of Remdesivir and methods for synthesis of same	Anzalp Pharmsolutions Pvt. Ltd.	Prodrugs Synthesis	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021154687 (B) US2021283150	ago 5, 2021	Methods for treating SARS-CoV-2 infections	Gilead Sciences, Inc.	Methods of Use	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021155119 (B)	ago 5, 2021	Therapeutics for COVID-19	Columbia University in the City of New York	Methods of Use	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN113214263 (B)	ago 6, 2021	A synthetic method of key intermediate of remdesivir	Beijing Chempion Technology Co., Ltd.	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN113214320 (B)	ago 6, 2021	Preparation method of remdesivir compound	Henan Taifeng Biotechnology Co., Ltd.	Prodrugs Synthesis	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021159050 (B)	ago 12, 2021	Compositions and methods for treating coronavirus infection	Hepalink USA Inc.	Methods of Use	Middle East respiratory syndrome coronavirus (MERS-CoV) infection Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
CN113248507 (B)	ago 13, 2021	Synthesis method of redosivir key intermediate 7-halogenated pyrrolo[1,2-f][1,2,4]triazine-4-amine	Shanghai Muse Health Tech Co., Ltd.	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN113248538 (B)	ago 13, 2021	A synthesis method of new synthesis remdesivir	Shanghai Muse Health Tech Co., Ltd.	Prodrugs Synthesis	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021160163 (B)	ago 19, 2021	Methods for prevention or treatment of virus-induced organ injury or failure with IL-22 dimer	Evive Biotech Corp. Ltd.	Fusion Proteins Methods of Use Therapeutic Proteins	Failure, respiratory Infection, viral Injury, lung Multi organ failure Sepsis Septic shock
WO2021160982 (B)	ago 19, 2021	Compositions and applications thereof	Nasaleze Patents Ltd.	Dosage Forms and Compositions	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021163199 (B)	ago 19, 2021	Treatment of infectious diseases	Durect Corp. Virginia Commonwealth University (VCU)	Methods of Use	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
US2021260201 (B)	ago 26, 2021	Extracellular vesicles for the treatment and prevention of infections and other diseases	Physis Biotechnologies, LLC	Carrier-mediated drug delivery Dosage Forms and Compositions Nanotechnology	Inflammatory disorders Pain Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN113336758 (B)	set 3, 2021	A new synthesis method of compound 7-iodo-pyrrolo[2,1-f][1,2,4]triazine-4-amine	Beijing Chempion Technology Co., Ltd.	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
CN113350323 (B)	set 7, 2021	Inhalation agent for inhibiting coronavirus and preparation method and application thereof	Guangzhou Hengnuokang Pharmaceutical Technology Co., Ltd. Shenzhen Resproly Bio-Pharmaceutical Co., Ltd.	Carrier-mediated drug delivery Dosage Forms and Compositions	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN113354684 (B)	set 7, 2021	A new compound and use thereof	Hebei Chunbai Biotechnology Co., Ltd.	Drug Substances	AIDS Coronavirus acute respiratory syndrome Hepatitis B (HBV) Infection, paramyxovirus
WO2021175250 (B)	set 10, 2021	Compounds and methods for treating diseases and/or conditions caused by coronavirus	Aptorum Therapeutics Ltd.	Combination Products	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021175296 (B)	set 10, 2021	Intermediate of remdesivir and preparation method therefor	Shanghai Institute of Materia Medica (SIMM) Suzhou Vigonvita Life Sciences Co., Ltd. Topharman Shanghai Co. Ltd.	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN113387954 (B)	set 14, 2021	Preparation method of Redisivir intermediate	Shanghai Institute of Materia Medica (SIMM) Topharman Shanghai Co. Ltd.	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
US2021284745 (B)	set 16, 2021	Treatment of cytokine release syndrome with GM-CSF antagonists	Kiniksa Pharmaceuticals, Ltd.	Antibodies Dosage Forms and Compositions	Coronavirus acute respiratory syndrome Inflammatory disorders Middle East respiratory syndrome coronavirus (MERS-CoV) infection Pneumonia, infectious Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021181044 (B) FR3108033	set 16, 2021	Composition comprising diltiazem for treating a viral infection caused by SARS-CoV-2 viruses	Centre National de la Recherche Scientifique (CNRS) Ecole Normale Supérieure (ENS) de Lyon Institut National de la Santé et de la Recherche Médicale (INSERM) Signia Therapeutics SAS Université Claude Bernard Lyon 1	Combination Products	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021183456 (B) US2021309733	set 16, 2021	Methods for treating coronavirus infection and resulting inflammation-induced lung injury	Humanigen, Inc.	Antibodies Methods of Use Vaccines	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN113402546 (B)	set 17, 2021	A dynamic dynamic splitting method for tail chain of intermediate of redsivir phosphate	Zhejiang Siwei Pharmaceutical Technology Co., Ltd.	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021187842 (B) KR2021116008	set 23, 2021	Pharmaceutical preparation for treating SARS-coronavirus infections, and medical use thereof	Institut Pasteur Korea	Methods of Use	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
WO2021194860 (B)	set 30, 2021	Tocilizumab and remdesivir combination therapy for COVID-19 pneumonia	Genentech, Inc.	Antibodies Combination Products	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021194918 (B)	set 30, 2021	Methods of treating pulmonary injury with CGRP inhibitors	Biohaven Pharmaceutical Holding Co. Ltd.	Methods of Use	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021201699 (B)	out 7, 2021	Antiviral treatment comprising blis containing probiotic products	BLIS Technologies Ltd.	Methods of Use	Infection, respiratory syncytial virus (RSV) Influenza A Influenza B Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021202907 (B)	out 7, 2021	Remdesivir and remdesivir analogs, solutions, and nanoparticle, liposomal, and microparticle compositions for treating viral infections	University of Michigan	Carrier-mediated drug delivery Methods of Use Nanotechnology	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021202912 (B)	out 7, 2021	Compositions for treatment of viral respiratory infections and methods of use thereof	Washington University	Carrier-mediated drug delivery Dosage Forms and Compositions Nanotechnology	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN113491673 (B)	out 12, 2021	A pharmaceutical composition containing redisivir	Qilu Pharmaceutical Co., Ltd.	Dosage Forms and Compositions	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
US11141419 (B) US2021338698	out 12, 2021	Use of iminosugars as prophylactic and therapy against COVID-19/SARS-CoV-2	Penn State Research Foundation	Methods of Use	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021207049 (B) US2021330685	out 14, 2021	Inhalation formulations of 1'-cyano substituted carbanucleoside analogs	Gilead Sciences, Inc.	Dosage Forms and Compositions	Infection, viral

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
WO2021207155 (B)	out 14, 2021	Airway epithelial alkaline therapy to treat viral respiratory infection	Airbase Breathing Co., Llc. Indiana University	Dosage Forms and Compositions	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN113509476 (B)	out 19, 2021	Redisivir composition and application thereof	Haerbin Huarui Biochemistry Pharmaceutical Industry Co., Ltd. Hangzhou METiS Pharmaceuticals Technology Co., Ltd.	Dosage Forms and Compositions	Ebola virus disease
WO2021202649 (B) US2021324066	out 21, 2021	Methods and treatment involving excess free LIGHT	Aevi Genomic Medicine, Inc.	Biomarkers Kits	Acute lung injury Acute respiratory distress syndrome (ARDS) Crohn's disease Pneumonia, infectious Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021208910 (B) CN113811309	out 21, 2021	Polymer preparation for treating virus infection, and preparation method therefor and use thereof	Shandong Hubble Kisen Biological Technology Co., Ltd.	Dosage Forms and Compositions	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021211738 (B)	out 21, 2021	Methods and compositions for antiviral treatment	Sanford Burnham Prebys Medical Discovery Institute The Scripps Research Institute	Methods of Use	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN113521020 (B)	out 22, 2021	Redisivir solid dosage form containing water-soluble acid	Qilu Pharmaceutical Co., Ltd.	Dosage Forms and Compositions	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
WO2021213288 (B)	out 28, 2021	Antiviral application of nucleoside analog or combination formulation containing nucleoside analog	Shanghai Institute of Materia Medica (SIMM) Wuhan Institute of Virology, Chinese Academy of Sciences	Drug Substances	Coronavirus acute respiratory syndrome Infection, Flavivirus Infection, respiratory syncytial virus (RSV) Influenza Viral hemorrhagic fever (filovrus infection)
WO2021215798 (B) KR2021129613 KR2021129579	out 28, 2021	Pharmaceutical composition for treating sars-coronavirus infection, and medical use thereof	Institut Pasteur Korea	Combination Products	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021216427 (B)	out 28, 2021	Nucleotide prodrug compounds	Ligand Pharmaceuticals, Inc.	Drug Substances Prodrugs	Infection, viral
WO2021219089 (B)	nov 4, 2021	SARS-CoV-2 inhibitors having covalent modifications for treating coronavirus infections	Insilico Medicine IP Ltd.	Drug Substances	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021221043 (B)	nov 4, 2021	Coronavirus infection therapeutic agent formed through combination of pyrazine derivative and another coronavirus infection therapeutic drug	FUJIFILM Toyama Chemical Co., Ltd.	Combination Products	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021221435 (B) KR2021133892	nov 4, 2021	Pharmaceutical composition for preventing or treating coronavirus disease-19	Institut Pasteur Korea Korea Advanced Institute of Science and Technology (KAIST)	Combination Products	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021222350 (B)	nov 4, 2021	Methods of use for single molecule compounds providing multi-target inhibition to treat covid-19	SignalRx Pharmaceuticals Inc	Combination Products	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021222584 (B)	nov 4, 2021	Inhibition of SARS-CoV-2 viral entry through administration of lactoferrin and uses thereof	University of Michigan	Dosage Forms and Compositions	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
WO2021222807 (B)	nov 4, 2021	Fatty acyl and fatty ether conjugates of remdesivir and its active metabolites as antivirals	AJK Biopharmaceutical LLC	Drug Substances Prodrugs	Middle East respiratory syndrome coronavirus (MERS-CoV) infection Severe acute respiratory syndrome coronavirus (SARS-CoV) infection Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021226478 (B)	nov 11, 2021	DHODH inhibitor for the treatment of COVID-19	PTC Therapeutics, Inc.	Combination Products	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021226479 (B)	nov 11, 2021	Inhaled statins for treatment of viral respiratory diseases	Beth Israel Deaconess Medical Center, Inc. InVixa, Inc. University of California VETERANS AFFAIRS MEDICAL CENTER	Methods of Use	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN113633617 (B)	nov 12, 2021	A solid dispersion containing redisivir, solid dosage form and preparation method	Qilu Pharmaceutical Co., Ltd.	Dosage Forms and Compositions	Infection, viral
IN202121046507 (B)	nov 12, 2021	Proliposomal dry powder inhaler of remdesivir	Rashtrasant Tukadoji Maharaj Nagpur University	Carrier-mediated drug delivery Dosage Forms and Compositions	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021231361 (B)	nov 18, 2021	Pharmaceutical formulation containing active metabolites of remdesivir for inhalation	Anovent Pharmaceutical (U.S.) LLC	Dosage Forms and Compositions	Infection, viral

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
CN113662927 (B)	nov 19, 2021	Nasal administration composition of redisivir	Yichang Humanwell Pharmaceutical Co., Ltd.	Dosage Forms and Compositions	Middle East respiratory syndrome coronavirus (MERS-CoV) infection Severe acute respiratory syndrome coronavirus (SARS-CoV) infection Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
IN202011020754 (B)	nov 19, 2021	Process for the preparation of remdesivir and intermediates thereof	Jubilant Generics Ltd.	Prodrugs Synthesis Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021233966 (B) EP3912627	nov 24, 2021	Methods for the treatment of coronavirus infections	Assistance Publique - Hopitaux de Marseille (AP-HM) Centre National de la Recherche Scientifique (CNRS) Ecole Normale Supérieure (ENS) de Lyon Institut de Recherche pour le Développement Institut National de la Santé et de la Recherche Médicale (INSERM) Université Claude Bernard Lyon 1 Université d'Aix-Marseille	Methods of Use	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
WO2021232169 (B)	nov 25, 2021	Synergistic anti-viral pharmaceutical composition containing targeting nanoparticles	Nuecology Biomedical Inc.	Combination Products	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021233966 (B) EP3912627	nov 25, 2021	Methods for the treatment of coronavirus infections	Assistance Publique - Hopitaux de Marseille (AP- HM) Centre National de la Recherche Scientifique (CNRS) Ecole Normale Supérieure (ENS) de Lyon Institut de Recherche pour le Développement Institut National de la Santé et de la Recherche Médicale (INSERM) Université Claude Bernard Lyon 1 Université d'Aix-Marseille	Methods of Use	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021236570 (B)	nov 25, 2021	Pharmaceutical formulation containing remdesivir and its active metabolites for dry powder inhalation	Anovent Pharmaceutical (U.S.) LLC	Carrier-mediated drug delivery Dosage Forms and Compositions	Infection, viral
WO2021237109 (B)	nov 25, 2021	Combination therapy for treatment of viral infections	Trailhead Biosystems, Inc.	Combination Products	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
IN202011021676 (B)	nov 26, 2021	Process for the preparation of remdesivir and novel intermediates thereof	Jubilant Generics Ltd.	Prodrugs Synthesis Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
IN202041021427 (B)	nov 26, 2021	Solid state form of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate and process for its preparation thereof	MSN Laboratories Ltd.	Processes	Infection, arenavirus Infection, paramyxovirus Middle East respiratory syndrome coronavirus (MERS-CoV) infection Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) Viral hemorrhagic fever (filovrus infection)
IN202121017287 (B)	nov 26, 2021	Synthesis of remdesivir with reduced and controlled particle size and inhalation formulations thereof	Ultratech India Ltd.	Synthesis	Infection, viral
WO2021240531 (B)	dez 2, 2021	Transmucosal dosage forms of remdesivir	Jubilant Generics Ltd.	Dosage Forms and Compositions	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021240543 (B) EP3915548 US2021369619	dez 2, 2021	Transmucosal pharmaceutical compositions of antiviral drugs	Jubilant Generics Ltd.	Dosage Forms and Compositions	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021242850 (B)	dez 2, 2021	Compositions and methods for preventing and treating SARS-CoV-2 infection	University of Michigan	Methods of Use	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
WO2021243157 (B) US2021393653	dez 2, 2021	Remdesivir treatment methods	Gilead Sciences, Inc.	Methods of Use	Ebola virus disease Infection, parainfluenza virus Infection, respiratory syncytial virus (RSV) Marburg virus hemorrhagic fever Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) Yellow fever
CN113735903 (B)	dez 3, 2021	Synthesis method of redisivir	Shandong Chengchuang Blue Sea Pharmaceutical Technology Co., Ltd.	Prodrugs Synthesis	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN113754692 (B)	dez 7, 2021	Asymmetric catalytic synthesis method of redosivir intermediate (S, S)-phosphoramidate	Shanghai Jiao Tong University (SJTU)	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
US2021379090 (B)	dez 9, 2021	Remdesivir oral delivery system	Abon Pharmaceuticals, LLC	Carrier-mediated drug delivery Dosage Forms and Compositions Nanotechnology	Infection, viral
WO2021245700 (B)	dez 9, 2021	Pharmaceutical lipid compositions of remdesivir	Jubilant Generics Ltd.	Carrier-mediated drug delivery Dosage Forms and Compositions	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021248022 (B)	dez 9, 2021	Methods of treating a coronavirus infection	The General Hospital Corp. (d/b/a Massachusetts General Hospital)	Combination Products	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
EP3922734 (B)	dez 15, 2021	Method for determining presence of a pre-determined viral RNA sequence in a sample	Ender diagnostics AG	Biomarkers	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2021248229 (B)	dez 16, 2021	Novel crystalline form of remdesivir	Apotex Inc.	Drug Substances Polymorphs	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
US2021393659 (B)	dez 23, 2021	Methods for treating arenaviridae and coronaviridae virus infections	Gilead Sciences, Inc.	Methods of Use	Lassa fever Middle East respiratory syndrome coronavirus (MERS-CoV) infection Severe acute respiratory syndrome coronavirus (SARS-CoV) infection
CN113827603 (B)	dez 24, 2021	Application of redsivir in preparing medicine for treating glioma	Beijing Jianmu Technology Co., Ltd.	Methods of Use	Glioblastoma
CN113827604 (B)	dez 24, 2021	Application of redisivir in preparing medicine for treating tumour or anti-tumour metastasis	Beijing Jianmu Technology Co., Ltd.	Methods of Use	Cancer
WO2021262715 (B) US2021393663	dez 30, 2021	Pharmaceutical formulation containing active metabolites of remdesivir or its analog for inhalation	Anovent Pharmaceutical (U.S.) LLC	Carrier-mediated drug delivery Dosage Forms and Compositions	Asthma Chronic obstructive pulmonary disease (COPD)
WO2021262799 (B)	dez 30, 2021	Anti-viral compounds and methods of using same	Flagship Pioneering, Inc.	Combination Products	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN113880846 (B)	jan 4, 2022	Preparation method of 7-iodo-pyrrolo [2, 1-F] [1, 2, 4] triazin-4-amine	Shandong Chengchuang Blue Sea Pharmaceutical Technology Co., Ltd. Shandong Chenghui Shuangda Pharmaceutical Co., Ltd.	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
WO2022008642 (B)	jan 13, 2022	Treatment of SARS-CoV-2 infection with a combination of targets	Apeiron Biologics AG	Combination Products Therapeutic Proteins	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2022012630 (B)	jan 20, 2022	Method for synthesizing C-nucleoside compound	Academy of Military Medical Sciences (AMMS) Chengdu Aupone Pharmaceutical Co., Ltd. Sichuan University (SCU)	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2022013353 (B) EP3939576	jan 20, 2022	Pharmaceutical compositions for treating infections by a neurotropic virus	Ceres Brain Therapeutics SAS Commissariat a l'Energie Atomique et aux Energies Alternatives (CEA)	Dosage Forms and Compositions	Infection, HIV Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2022015982 (B)	jan 20, 2022	Compositions and methods for treating viral infections	University of California	Methods of Use	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2022016073 (B)	jan 20, 2022	Pharmaceutical compositions for delivery of remdesivir by inhalation	TFF Pharmaceuticals, Inc. University of Texas System	Carrier-mediated drug delivery Dosage Forms and Compositions Polymorphs	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN113952457 (B)	jan 21, 2022	Application of tiremimide or pharmaceutical composition containing teremimide in anti-coronavirus	Cinkate Pharmaceutical Chemical Intermediate (Shanghai) Co., Ltd.	Combination Products	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2022020793 (B)	jan 27, 2022	Antiviral prodrugs, pharmaceutical formulations, and methods	University of California	Drug Substances Prodrugs	Coronavirus acute respiratory syndrome

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
CN113980024 (B)	jan 28, 2022	Preparation method of redisivir intermediate compound	Hunan Huateng Pharmaceutical Co., Ltd.	Prodrugs Synthesis Intermediates	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2022020940 (B)	fev 3, 2022	Novel salts of remdesivir	Apotex Inc.	Drug Substances	Infection, viral Influenza A
WO2022026622 (B)	fev 3, 2022	Treatment of viral diseases	National Research Council of Canada (NRC)	Methods of Use	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2022029275 (B)	fev 10, 2022	Combination of nicotinamide mononucleotide derivatives and other therapeutic agents for use in the treatment of coronavirus infections and COVID- 19	Nuvamid SA	Combination Products	Coronavirus acute respiratory syndrome
WO2022029604 (B)	fev 10, 2022	Microemulsion drug delivery system for treatment of acute respiratory distress syndrome	Council for Scientific and Industrial Research (CSIR) (ZA)	Methods of Use	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2022035286 (B) KR2022021888	fev 17, 2022	Pharmaceutical composition for prevention or treatment of coronavirus infection disease-19	Korea United Pharm. Inc.	Combination Products	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
WO2022035911 (B)	fev 17, 2022	Methods of treating coronavirus infections by co-administering an FKBP ligand and an antiviral agent	Tutela Pharmaceuticals Inc.	Combination Products	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
CN114053289 (B)	fev 18, 2022	Application of redisivir in preparing medicine for preventing and treating neurodegenerative diseases	Beijing Jianmu Technology Co., Ltd.		
WO2022040761 (B)	mar 3, 2022	Dendrimer-drug conjugate	Starpharma Pty. Ltd.	Drug Conjugates Drug Substances	Coronavirus acute respiratory syndrome
WO2022047441 (B)	mar 3, 2022	Formulations of anti-viral compounds	Emphascience Inc.	Dosage Forms and Compositions	Infection, viral
US2022071928 (B)	mar 10, 2022	Polyamine transport inhibitors as antivirals	Boston University University of Central Florida (UCF)		

Patent Family Number	Publication Date	Title	Applicant	Subject Matter	Condition
WO2022055449 (B)	mar 17, 2022	Use of active substances with antiviral, anti malarial, and/or mucolytic properties in the treatment of viral lung diseases including COVID-19 by soft mist inhaler or vibration mesh technology nebulizer through inhalation route	Istanbul Ueniversitesi		